Monte Rosa Therapeutics (Monte Rosa Therapeutics) EV-to-EBIT

: -0.76 (As of Today)

View and export this data going back to 2021. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Monte Rosa Therapeutics's Enterprise Value is $109.54 Mil. Monte Rosa Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-143.31 Mil. Therefore, Monte Rosa Therapeutics's EV-to-EBIT for today is -0.76.

The historical rank and industry rank for Monte Rosa Therapeutics's EV-to-EBIT or its related term are showing as below:

GLUE' s EV-to-EBIT Range Over the Past 10 Years
Min: -125.9 Med: 0 Max: 0.33
Current: -0.76

During the past 5 years, the highest EV-to-EBIT of Monte Rosa Therapeutics was 0.33. The lowest was -125.90. And the median was 0.00.

GLUE's EV-to-EBIT is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 8.685 vs GLUE: -0.76

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Monte Rosa Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $96.92 Mil. Monte Rosa Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-143.31 Mil. Monte Rosa Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -147.87%.

Monte Rosa Therapeutics EV-to-EBIT Historical Data

The historical data trend for Monte Rosa Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => -8.29 [3] => -1.42 [4] => -0.68 )

Monte Rosa Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-8.29

-1.42

-0.68

Monte Rosa Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT													-1.42	-1.63	-1.39	-0.76	-0.68

Competitive Comparison

For the Biotechnology subindustry, Monte Rosa Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monte Rosa Therapeutics EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Monte Rosa Therapeutics's EV-to-EBIT falls into.

Monte Rosa Therapeutics EV-to-EBIT Calculation

Monte Rosa Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	109.535	/	-143.31
	=	-0.76

Monte Rosa Therapeutics's current Enterprise Value is $109.54 Mil.
Monte Rosa Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-143.31 Mil.

Monte Rosa Therapeutics (NAS:GLUE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Monte Rosa Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-143.31	/	96.91813
	=	-147.87 %

Monte Rosa Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $96.92 Mil.
Monte Rosa Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-143.31 Mil.

Monte Rosa Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Monte Rosa Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Monte Rosa Therapeutics (Monte Rosa Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monte Rosa Therapeutics Inc (NAS:GLUE) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Suite 102, Boston, MA, USA, 02210

Website

https://www.monterosatx.com

Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.

Executives

Edmund Dunn	officer: Principal Accounting Officer	MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON MA 02210
Anthony M. Manning	director	C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jan Skvarka	director	C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Philip Nickson	officer: General Counsel	MONTE ROSA THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Julian G Jones	officer: Chief Business Officer	MONTE ROSA THERAPEUTICS, INC., 645 SUMMER STREET, SUITE 102, BOSTON MA 02210
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Edward T Mathers	10 percent owner	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Kimberly Blackwell	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Cormorant Private Healthcare Fund Ii, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
New Enterprise Associates 17, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093